SOLARA ACTIVE PHA SCI LTD
SOLARA · Pharma · NSE
₹603
Current Market Price
Fair Value (DCF)
₹750
Discount to FV
+24.6%
Updated just now
YieldIQ Score
52/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
53%
ROE
0.0%
Debt/Equity
0.73
WACC
9.7%
Market Cap
₹2,875 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.8%
Return on capital employed
EV / EBITDA
15.8×
Enterprise multiple
Debt / EBITDA
3.6×
Leverage vs earnings
Interest Coverage
1.0×
EBIT covers interest
Current Ratio
0.77×
Short-term liquidity
Asset Turnover
0.61×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-0.3%
3-year revenue growth
Revenue CAGR (5Y)
-3.3%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹602.5
Bear case
Margin of Safety -66.2%
Implied upside -39.8%
Base case
Margin of Safety +16.5%
Implied upside +19.7%
Bull case
Margin of Safety +30.0%
Implied upside +42.9%
Ratio Trends
SOLARA · last 7 annual periods
ROE
0.0%
ROCE
10.8%
Operating Margin
—
Debt / Equity
0.73×
PE
315.0×
EV / EBITDA
13.0×
Historical Financials
SOLARA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1231 Cr | ₹1379 Cr | ₹1238 Cr | ₹1284 Cr | ₹1369 Cr | +2.7% |
| EBITDA | ₹88.5 Cr | ₹150 Cr | ₹-285 Cr | ₹215 Cr | ₹187 Cr | +20.6% |
| EBIT | ₹-15.8 Cr | ₹45.3 Cr | ₹-383 Cr | — | — | — |
| PAT | ₹-58.1 Cr | ₹-22.2 Cr | ₹-567 Cr | ₹0.5 Cr | ₹-7.4 Cr | — |
| EPS (diluted) | ₹-16.18 | ₹-6.16 | ₹-157.62 | — | — | — |
| CFO | ₹-242 Cr | ₹156 Cr | ₹109 Cr | ₹213 Cr | ₹153 Cr | — |
| CapEx | ₹-209 Cr | ₹-111 Cr | ₹-41.1 Cr | ₹-39.9 Cr | ₹-52.8 Cr | — |
| FCF | ₹-451 Cr | ₹44.9 Cr | ₹67.8 Cr | ₹173 Cr | ₹100 Cr | — |
| Total Assets | ₹2945 Cr | ₹2899 Cr | ₹2351 Cr | ₹2232 Cr | ₹2333 Cr | -5.7% |
| Total Debt | ₹1037 Cr | ₹1013 Cr | ₹1012 Cr | ₹796 Cr | ₹687 Cr | -9.8% |
| Shareholders' Equity | ₹1525 Cr | ₹1500 Cr | ₹934 Cr | ₹1094 Cr | ₹1253 Cr | -4.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SOLARA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 HIKAL HIKAL | — | — | Pending | -4.1% | — |
 UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
MOREPENLAB MOREPENLAB | — | — | Pending | 7.6% | — |
 IOLCP IOLCP | — | — | Pending | 7.7% | 15.5× |
BLISSGVS BLISSGVS | — | — | Pending | 10.8% | 17.7× |
Click a ticker to view its fair-value analysis.
Dividend History
4 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹2.76/sh
Last payout
2021-08-18
₹2.76
Peak payout
₹4.61
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. SOLARA ACTIVE PHA SCI LTD (SOLARA.NS) trades at 602.50 vs a model fair value of 750.47, a gap of 24.6%. Piotroski F-score: 5/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SOLARA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SOLARA →
Compare
Head-to-head with peers
Compare SOLARA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SOLARANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.